Literature DB >> 19002566

Concentration-dependent effect of naringin on intestinal absorption of beta(1)-adrenoceptor antagonist talinolol mediated by p-glycoprotein and organic anion transporting polypeptide (Oatp).

Yoshiyuki Shirasaka1, Yan Li, Yuta Shibue, Erika Kuraoka, Hildegard Spahn-Langguth, Yukio Kato, Peter Langguth, Ikumi Tamai.   

Abstract

PURPOSE: The purpose of this study is to clarify the impact of P-gp and Oatp on intestinal absorption of the beta(1)-adrenoceptor antagonist talinolol.
METHODS: P-gp-mediated transport was measured in LLC-PK1/MDR1 cells. Oatp-mediated uptake was evaluated with Xenopus oocytes expressing Oatp1a5. Rat intestinal permeability was measured by the in situ closed loop method. In vivo absorption was pharmacokinetically assessed by measuring plasma concentration after oral administration in rats.
RESULTS: In LLC-PK1/MDR1 cells, the permeability of talinolol was markedly higher in the secretory direction than in the absorptive one. The uptake of talinolol by Xenopus oocytes expressing Oatp1a5 was significantly increased compared with that by water-injected oocytes. Naringin inhibited talinolol uptake by Oatp1a5 (IC (50) = 12.7 microM). The reported IC (50) value of naringin for P-gp-mediated transport of talinolol is approximately 2,000 microM. Rat intestinal permeability of talinolol was significantly decreased in the presence of 200 microM naringin, but was significantly increased by 2,000 microM naringin. Similar results were obtained in in vivo absorption studies in rats.
CONCLUSION: The absorption behavior of talinolol can be explained by the involvement of both P-gp and Oatp, based on characterization of talinolol transport by Oatp1a5 and P-gp, and the effects of naringin.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19002566     DOI: 10.1007/s11095-008-9771-4

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  43 in total

Review 1.  Pharmacokinetic strategies in deciphering atypical drug absorption profiles.

Authors:  Honghui Zhou
Journal:  J Clin Pharmacol       Date:  2003-03       Impact factor: 3.126

2.  Transporter-mediated intestinal absorption of fexofenadine in rats.

Authors:  Akihiro Kikuchi; Takashi Nozawa; Takeru Wakasawa; Tomoji Maeda; Ikumi Tamai
Journal:  Drug Metab Pharmacokinet       Date:  2006-08       Impact factor: 3.614

3.  Molecular mechanisms of the naringin low uptake by intestinal Caco-2 cells.

Authors:  Franck Tourniaire; Meryl Hassan; Marc André; Odette Ghiringhelli; Christian Alquier; Marie-Josèphe Amiot
Journal:  Mol Nutr Food Res       Date:  2005-10       Impact factor: 5.914

4.  Regional intestinal permeability in rats of compounds with different physicochemical properties and transport mechanisms.

Authors:  U Fagerholm; A Lindahl; H Lennernäs
Journal:  J Pharm Pharmacol       Date:  1997-07       Impact factor: 3.765

5.  Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport.

Authors:  Yoshihisa Shitara; Daisuke Sugiyama; Hiroyuki Kusuhara; Yukio Kato; Takaaki Abe; Peter J Meier; Tomoo Itoh; Yuichi Sugiyama
Journal:  Pharm Res       Date:  2002-02       Impact factor: 4.200

6.  Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family.

Authors:  I Tamai; J Nezu; H Uchino; Y Sai; A Oku; M Shimane; A Tsuji
Journal:  Biochem Biophys Res Commun       Date:  2000-06-24       Impact factor: 3.575

7.  Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans.

Authors:  U I Schwarz; T Gramatté; J Krappweis; A Berndt; R Oertel; O von Richter; W Kirch
Journal:  Clin Pharmacol Ther       Date:  1999-03       Impact factor: 6.875

8.  Active intestinal secretion of new quinolone antimicrobials and the partial contribution of P-glycoprotein.

Authors:  K Naruhashi; I Tamai; N Inoue; H Muraoka; Y Sai; N Suzuki; A Tsuji
Journal:  J Pharm Pharmacol       Date:  2001-05       Impact factor: 3.765

9.  P-glycoprotein transporters and the gastrointestinal tract: evaluation of the potential in vivo relevance of in vitro data employing talinolol as model compound.

Authors:  H Spahn-Langguth; G Baktir; A Radschuweit; A Okyar; B Terhaag; P Ader; A Hanafy; P Langguth
Journal:  Int J Clin Pharmacol Ther       Date:  1998-01       Impact factor: 1.366

10.  Effect of P-glycoprotein expression levels on the concentration-dependent permeability of drugs to the cell membrane.

Authors:  Yoshiyuki Shirasaka; Toshiyasu Sakane; Shinji Yamashita
Journal:  J Pharm Sci       Date:  2008-01       Impact factor: 3.534

View more
  10 in total

1.  Substrate- and dose-dependent drug interactions with grapefruit juice caused by multiple binding sites on OATP2B1.

Authors:  Yoshiyuki Shirasaka; Takanori Mori; Yukiko Murata; Takeo Nakanishi; Ikumi Tamai
Journal:  Pharm Res       Date:  2014-02-19       Impact factor: 4.200

2.  Simulations of the nonlinear dose dependence for substrates of influx and efflux transporters in the human intestine.

Authors:  Michael B Bolger; Viera Lukacova; Walter S Woltosz
Journal:  AAPS J       Date:  2009-05-12       Impact factor: 4.009

Review 3.  The role of transporters in the pharmacokinetics of orally administered drugs.

Authors:  Sarah Shugarts; Leslie Z Benet
Journal:  Pharm Res       Date:  2009-06-30       Impact factor: 4.200

4.  Intestinal absorption of HMG-CoA reductase inhibitor pravastatin mediated by organic anion transporting polypeptide.

Authors:  Yoshiyuki Shirasaka; Kensuke Suzuki; Takeo Nakanishi; Ikumi Tamai
Journal:  Pharm Res       Date:  2010-08-05       Impact factor: 4.200

5.  Effects of one-time apple juice ingestion on the pharmacokinetics of fexofenadine enantiomers.

Authors:  Yumiko Akamine; Masatomo Miura; Hisakazu Komori; Shun Saito; Hiroyuki Kusuhara; Ikumi Tamai; Ichiro Ieiri; Tsukasa Uno; Norio Yasui-Furukori
Journal:  Eur J Clin Pharmacol       Date:  2014-06-07       Impact factor: 2.953

6.  Effect of grapefruit juice on the pharmacokinetics of tolvaptan, a non-peptide arginine vasopressin antagonist, in healthy subjects.

Authors:  Susan E Shoaf; Suresh Mallikaarjun; Patricia Bricmont
Journal:  Eur J Clin Pharmacol       Date:  2011-08-19       Impact factor: 2.953

7.  Effect of Multi Drug Resistance Protein 4 (MRP4) Inhibition on the Pharmacokinetics and Pharmacodynamics of Ciprofloxacin in Normal and Rats with LPS-Induced Inflammation.

Authors:  V Gangadhara N V Prasad; Satyanarayana Achanta; Yathiraja Rao Tammineni; Gopala Reddy Alla; Madhava Rao Thirtham; G S Rao
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-12       Impact factor: 2.441

8.  Interaction of macrolide antibiotics with intestinally expressed human and rat organic anion-transporting polypeptides.

Authors:  Tian Lan; Anuradha Rao; Jamie Haywood; Charles B Davis; Chao Han; Eric Garver; Paul A Dawson
Journal:  Drug Metab Dispos       Date:  2009-09-09       Impact factor: 3.922

Review 9.  The grapefruit: an old wine in a new glass? Metabolic and cardiovascular perspectives.

Authors:  P M Owira; J A Ojewole
Journal:  Cardiovasc J Afr       Date:  2010 Sep-Oct       Impact factor: 1.167

Review 10.  P-glycoprotein: new insights into structure, physiological function, regulation and alterations in disease.

Authors:  Iman Imtiyaz Ahmed Juvale; Azzmer Azzar Abdul Hamid; Khairul Bariyyah Abd Halim; Ahmad Tarmizi Che Has
Journal:  Heliyon       Date:  2022-06-22
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.